Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
November 30, 2022 07:00 ET
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
November 14, 2022 06:10 ET
|
Eliem Therapeutics, Inc.
Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety...
Eliem Therapeutics to Participate at Two Upcoming Investor Conferences
November 08, 2022 07:00 ET
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal...
Eliem Therapeutics Provides Update on Pipeline Progress
October 05, 2022 07:00 ET
|
Eliem Therapeutics, Inc.
Company is positioned to initiate Phase 2a trial in major depressive disorder (MDD) in the first quarter of 2023 ETX-155 demonstrating exposures in single dose 60-milligram cohorts of ongoing Phase 1...
Eliem Therapeutics Reports Second Quarter Financial and Business Highlights
August 15, 2022 06:10 ET
|
Eliem Therapeutics, Inc.
Initiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022 Capital now expected to fund operations into 2025 SEATTLE and CAMBRIDGE, United Kingdom, Aug. 15, 2022 (GLOBE...
Eliem Therapeutics Provides ETX-810 Program Update
August 02, 2022 07:00 ET
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder
July 18, 2022 07:00 ET
|
Eliem Therapeutics, Inc.
Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023 Sufficient capital expected to fund operations until mid-2024...
Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022
July 07, 2022 07:00 ET
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)
June 27, 2022 16:01 ET
|
Eliem Therapeutics, Inc.
Topline data from the Phase 2a clinical trial are expected in the third quarter of 2022 Virtual investor event to be held in July 2022 SEATTLE and CAMBRIDGE, United Kingdom, June 27, 2022 (GLOBE...
Eliem Therapeutics Reports First Quarter Financial and Business Highlights
May 16, 2022 06:10 ET
|
Eliem Therapeutics, Inc.
SEATTLE and CAMBRIDGE, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...